A Study on the Etiological Factors of Bilharzial Bladder Cancer in Egypt: 4. β-Carotene and Vitamin a Level in Serum

1982 ◽  
Vol 68 (1) ◽  
pp. 19-22 ◽  
Author(s):  
Abdelbaset Anvver El-Aaser ◽  
Mahmoud Mohamed El-Merzabani ◽  
K.A. Abdel-Reheem ◽  
B.M. Hamza
Keyword(s):  
Bladder Cancer ◽  
Vitamin A ◽  
Cell Carcinoma ◽  
Cancer Patients ◽  
Transitional Cell ◽  
Normal Male ◽  
Tumor Type ◽  
Male Subjects ◽  
Β Carotene

The possible role of vitamin A in the pathogenesis of bilharzial bladder cancer among Egyptians, particularly as it relates to the histopathologic tumor type, was investigated. Bilharzial patients and bladder cancer patients with squamous cell carcinoma, the most prevalent type in Egypt, showed significantly lower levels of vitamin A than normal male subjects. In contrast, bladder cancer patients with transitional cell carcinoma had levels that were not significantly different from normal male subjects. The possible role of vitamin A in the etiology of bilharzial bladder cancer is discussed.

Perineal Urethrectomy for Transitional Urethral Tumours in Bladder Cancer Patients

1993 ◽  
Vol 60 (3) ◽  
pp. 279-282
Author(s):  
P. De Carli ◽  
M. Marcellini ◽  
H. Fattahi ◽  
G. Mainiero ◽  
B.M. Ciammarughi
Keyword(s):  
Bladder Cancer ◽  
Urinary Tract ◽  
Surgical Treatment ◽  
Transitional Cell Carcinoma ◽  
Cell Carcinoma ◽  
Cancer Patients ◽  
Transitional Cell ◽  
Urethral Carcinoma ◽  
Bladder Substitution

Transitional cell carcinoma is often multicentric in the urinary tract and urethral tumours are not infrequent in bladder cancer patients. The occurrence of urethral carcinoma is simultaneous or recurrent after radical cystectomy. The management of urethral neoplasms and results of 12 simultaneous and 10 post-cystectomy cases treated with perineal urethrectomy are reported. The Authors debate the role of primary and secondary surgical treatment and the perineal or prepubic technique. One case of urethral recurrence after orthotopic bladder substitution emphasizes that patients must be accurately evaluated to exclude urethral disease before cystoprostatectomy, and monitored for carcinoma of urethral remnant.

scholarly journals Pathogenic and Diagnostic Potential of BLCA-1 and BLCA-4 Nuclear Proteins in Urothelial Cell Carcinoma of Human Bladder

2012 ◽  
Vol 2012 ◽  
pp. 1-5 ◽  
Author(s):  
Matteo Santoni ◽  
Francesco Catanzariti ◽  
Daniele Minardi ◽  
Luciano Burattini ◽  
Massimo Nabissi ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Cell Carcinoma ◽  
Matrix Protein ◽  
Transitional Cell ◽  
High Recurrence Rate ◽  
Diagnostic Potential ◽  
Bladder Cancer Cells ◽  
Previously Treated Patients ◽  
Previously Treated

Transitional cell carcinoma (TCC) of the bladder is one of the most common malignancies of genitourinary tract. Patients with bladder cancer need a life-long surveillance, directly due to the relatively high recurrence rate of this tumor. The use of cystoscopy represents the gold standard for the followup of previously treated patients. Nevertheless, several factors, including cost and invasiveness, render cystoscopy not ideal for routine controls. Advances in the identification of specific alterations in the nuclear structure of bladder cancer cells have opened novel diagnostic landscapes. The members of nuclear matrix protein family BLCA-1 and BLCA-4, are currently under evaluation as bladder cancer urinary markers. They are involved in tumour cell proliferation, survival, and angiogenesis. In this paper, we illustrate the role of BLCA-1 and BLCA-4 in bladder carcinogenesis and their potential exploitation as biomarkers in this cancer.

scholarly journals IS NEOBLADDER SAFE FOR HIGH GRADE BLADDER CANCER PATIENTS?: EVALUATION OF RADICAL CYSTECTOMY COMPLICATIONS AND ILEAL NEOBLADDER RECONSTRUCTION IN AMC KARIADI GENERAL HOSPITAL

2019 ◽  
Vol 26 (1) ◽  
Author(s):  
Irene Stephanie ◽  
Mohamad Adi Soedarso
Keyword(s):  
Renal Failure ◽  
Bladder Cancer ◽  
Cell Carcinoma ◽  
Cancer Patients ◽  
General Hospital ◽  
Radical Cystectomy ◽  
Transitional Cell ◽  
High Grade ◽  
Ileal Neobladder ◽  
Urinary Leakage

Objective: The purpose of this study was to evaluate complications of ileal neobladder reconstruction in high grade bladder cancer patients. Material & Methods: The descriptive study included 12 patients who underwent radical cystectomy and bladder reconstruction with ileal neobladder in Academic Medical Center Kariadi General Hospital Semarang from 2009 until 2016. Base data recorded retrospectively and followed at outpatient clinic. The complications were evaluated from perioperative care, postoperative care, and outpatients clinic. Clavien Dindo classification use to rank complication. Results: The average ages distribution range from 39-70 year. There were 2 patients with comorbid of renal failure, 11 patients with history of TUR and 1 patient underwent adjuvant external radiation. There were 11 patients in high grade bladder cancer (≥T3) and 1 patient with T2. Of the 8 patients underwent orthotopic neobladder procedure and 3 patients underwent cutaneous w-shape procedure. From the histopathology results, 10 patients with high grade transitional cell carcinoma, and 2 patients with invasive urothelial cell carcinoma. There were complication caused by neobladder-related of 1 patient with urinary leakage from ureteroileal anastomose, 1 patient with peritonitis caused by ileo-ileal anastomose leakage, and 1 patients with bowel necrosis caused by internal hernia who need re-operation. All neobladder related complication were 4/33%. From neobladder nonrelated of 1 patient with chronic renal disease and sepsis, and 1 patient with acute renal failure and hyperchlor metabolic acidosis. All of neobladder related complications described above end with mortality (2/16%), except the urinary leakage. Conclusion: Our complication and mortality radical cystectomy - neobladder related rate were 33% and 16% compare with literature show 28-64% and 5.1-8.1%, respectively. Patients selection (<T3, no comorbid) and experience according high volume operation can reduced the mortality rate.

Upper tract transitional cell carcinoma following or related to bladder cancer: Controversies

1996 ◽  
Vol 63 (1) ◽  
pp. 25-28
Author(s):  
S. Cosciani Cunico ◽  
E. Frego ◽  
M. Scanzi ◽  
T. Zanotelli ◽  
E. Panizza ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Urinary Tract ◽  
Transitional Cell Carcinoma ◽  
Cell Carcinoma ◽  
Vesicoureteral Reflux ◽  
Transitional Cell ◽  
Latency Period ◽  
Upper Urinary Tract

— The incidence of upper urinary tract transitional cell carcinoma (UTTCC) following a bladder cancer has been studied in 1731 urothelial tumours from 1984 to 1995. The UTTCC were 88: 59 primitive, 6 synchronous and 23 metachronous after a bladder cancer (1672). Of the 23 metachronous UTTCC, 17 followed TURBT (17/1310 = 1.3%): the latency period was very long (64.8 months); grading and staging were mostly similar to the foregoing bladder tumours. A vesicoureteral reflux raised the metachronous UTTCC rate to 17.6%. A neoplastic distal ureter was found during radical cystectomy in 2.24%. During the follow-up of 362 radical cystectomies 6 (1.65%) metachronous UTTCC were recorded. A metachronous UTTCC is always a poor prognostic sign. There are some controversies concerning this topic such as: the role of IVP and urine cytology in the follow-up of bladder cancer, the management of a vesicoureteral reflux in bladder cancer and the choice of a urinary diversion in the event of an upper urinary tract at high risk for UTTCC.

405: Previous History of Bladder Cancer is an Independent Prognostic Factor for Upper Tract Transitional Cell Carcinoma

2007 ◽  
Vol 177 (4S) ◽  
pp. 135-135
Author(s):  
Eiji Kikuchi ◽  
Akira Miyajima ◽  
Ken Nakagawa ◽  
Mototsugu Oya ◽  
Takashi Ohigashi ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Prognostic Factor ◽  
Transitional Cell Carcinoma ◽  
Cell Carcinoma ◽  
Transitional Cell ◽  
Previous History ◽  
Independent Prognostic Factor ◽  
Upper Tract ◽  
History Of

1763: Stage Migration of upper Tract Transitional Cell Carcinoma: An Argument for the Continued Role of Endourologic Diagnosis and Treatment

2004 ◽  
Vol 171 (4S) ◽  
pp. 466-466
Author(s):  
Stephen A. Boorjian ◽  
Casey K. Ng ◽  
Ravi Munver ◽  
R. Ernest Sosa ◽  
E. Darracott Vaughan ◽  
...  
Keyword(s):  
Transitional Cell Carcinoma ◽  
Cell Carcinoma ◽  
Transitional Cell ◽  
Diagnosis And Treatment ◽  
Stage Migration ◽  
Upper Tract

scholarly journals Paraneoplastic production of heparin-like anticoagulant in a patient with metastatic transitional cell carcinoma

2013 ◽  
Vol 3 (5) ◽  
pp. 61 ◽  
Author(s):  
Kelly N. Fahl ◽  
Stephen A. Poon ◽  
Ketan K. Badani ◽  
Mitchell C. Benson
Keyword(s):  
Bladder Cancer ◽  
Breast Carcinoma ◽  
Liver Failure ◽  
Transitional Cell Carcinoma ◽  
Cell Carcinoma ◽  
Hematological Malignancies ◽  
Transitional Cell ◽  
Carcinoma Breast ◽  
Severe Coagulopathy

It has been reported that patients with bladder cancer have widelyvarying paraneoplastic consequences, including metabolic, dermatologic,myopathic and neurologic disturbances. We report a case of a52-year-old man with advanced transitional cell carcinoma and livermetastases, who developed a severe coagulopathy following roboticradical cystoprostatectomy due to circulating heparin-like substancesprior to onset of liver failure. Heparin-like anticoagulant production isa rare paraneoplastic effect documented in concert with transitionalcell carcinoma, breast carcinoma and hematological malignancies.

Repeated Intravesical Instillations of an Adenoviral Vector in Patients With Locally Advanced Bladder Cancer: A Phase I Study of p53 Gene Therapy

2003 ◽  
Vol 21 (12) ◽  
pp. 2247-2253 ◽  
Author(s):  
Lance C. Pagliaro ◽  
Afsaneh Keyhani ◽  
Dallas Williams ◽  
Denise Woods ◽  
Baoshun Liu ◽  
...  
Keyword(s):  
Gene Therapy ◽  
Bladder Cancer ◽  
Gene Transfer ◽  
Transitional Cell Carcinoma ◽  
Cell Carcinoma ◽  
Locally Advanced ◽  
Transitional Cell ◽  
P53 Gene ◽  
Advanced Bladder Cancer ◽  
Intravesical Instillations

Purpose: We investigated the feasibility, safety, and biologic activity of adenovirus-mediated p53 gene transfer in patients with locally advanced bladder cancer. Patients and Methods: Patients with measurable, locally advanced transitional-cell carcinoma of the bladder who were not candidates for cystectomy were eligible. On a 28-day cycle, intravesical instillations of INGN 201 (Ad5CMV-p53) were administered on days 1 and 4 at three dose levels (1010 particles to 1012 particles) or on either 4 or 8 consecutive days at a single dose level (1012 particles). Results: Thirteen patients received a total of 22 courses without dose-limiting toxicity. Specific transgene expression was detected by reverse transcriptase polymerase chain reaction in bladder biopsy tissue from two of seven assessable patients. There were no changes in p53, p21waf1/cip1, or bax protein levels in bladder epithelium evident from immunohistochemical analysis of 11 assessable patients. Outpatient administration of multiple courses was feasible and well tolerated. A patient with advanced superficial bladder cancer showed evidence of tumor response. Conclusion: Intravesical instillation of Ad5CMV-p53 is safe, feasible, and biologically active when administered in multiple doses to patients with bladder cancer. Observations from this study indicate that this treatment has an antitumor effect in superficial transitional-cell carcinoma. Improvements in the efficiency of gene transfer and the levels of gene expression are required to develop more effective gene therapy for bladder cancer.

Sign in / Sign up

Export Citation Format

Share Document